These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 38439728)

  • 41. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study.
    Rose E; Wever S; Zilliken D; Linse R; Haustein UF; Bröcker EB
    J Dtsch Dermatol Ges; 2005 Mar; 3(3):200-6. PubMed ID: 16372814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
    Miše J; Jukić IL; Marinović B
    Front Immunol; 2022; 13():884931. PubMed ID: 35592312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
    Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M
    Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study.
    Russo I; Miotto S; Saponeri A; Alaibac M
    Expert Opin Biol Ther; 2020 Jun; 20(6):673-678. PubMed ID: 32027810
    [No Abstract]   [Full Text] [Related]  

  • 45. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ; Engert A; Krieg T; Hunzelmann N
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.
    Özgen Z; Aksoy H; Akın Çakıcı Ö; Koku Aksu AE; Erdem O; Kara Polat A; Gürel MS
    Dermatol Ther; 2022 May; 35(5):e15417. PubMed ID: 35243732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature.
    Fuertes I; Guilabert A; Mascaró JM; Iranzo P
    Dermatology; 2010 Aug; 221(1):13-6. PubMed ID: 20389028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
    Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
    Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus.
    Saha M; Powell AM; Bhogal B; Black MM; Groves RW
    Br J Dermatol; 2010 Apr; 162(4):790-7. PubMed ID: 19922532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab exerts a dual effect in pemphigus vulgaris.
    Eming R; Nagel A; Wolff-Franke S; Podstawa E; Debus D; Hertl M
    J Invest Dermatol; 2008 Dec; 128(12):2850-8. PubMed ID: 18563178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies against desmoglein 2 are not pathogenic in pemphigus.
    Miguel MCB; Julio TA; Vernal S; de Paula NA; Lieber A; Roselino AM
    An Bras Dermatol; 2022; 97(2):145-156. PubMed ID: 35058080
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
    Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
    Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.